Fake painkillers are circulating in the Netherlands, authorities warn after man dies
The pills were bought online without a prescription, according to the Trimbos Institute, a Dutch scientific research agency.
They did not contain oxycodone – which is prescribed for patients with severe pain – but rather nitazenes, which are synthetic opioids that are much stronger than oxycodone, morphine, or fentanyl.
The drugs are so potent that only a few milligrams can cause fatal breathing problems, according to Trimbos. The effects also last longer, raising the risk of an overdose.
Related
What the EU drugs agency chief is most worried about in 2025
Police in Amsterdam are still trying to identify where the man who died got the fake oxycodone. But his death is one of several health crises tied to synthetic drugs in the Netherlands recently.
The Dutch Health and Youth Care Inspectorate (IGJ) said multiple people have received emergency medical care after taking pills that were sold online as oxycodone but turned out to contain nitazenes.
The drugs are sold online and on social media, the inspectorate said. They look like oxycodone and typically have original-looking packaging – making them 'almost indistinguishable' from the real thing, it added.
Related
From cannabis to cocaine: What are the most commonly used illicit drugs in the EU?
'This shows how dangerous it is to order prescription drugs online,' IGJ chief inspector Henk de Groot said in a statement.
'It may look real, but you have absolutely no idea what you are buying'.
The warning comes amid an uptick in the availability of nitazenes and other synthetic opioids in parts of Europe, according to the European Union Drugs Agency, which described them as an 'important emerging threat'.
Related
'Missing piece of the jigsaw': Glasgow hopes safe injection site will curb overdose deaths
Trimbos urged people to avoid buying pain medication online and said people should call for emergency help if they begin feeling unwell after taking oxycodone.
Meanwhile, IGJ said people can report websites selling prescription medicines to investigators.
'For drugs, go to your doctor and pharmacy,' de Groot said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Press Release: Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseases Paris, August 14, 2025. The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton's tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD). EMA grants orphan designation to investigational therapies addressing rare, life-threatening or debilitating medical diseases or conditions that affect no more than 5 in 10,000 persons in the EU. Rilzabrutinib for the treatment of IgG4-related disease was evaluated in a phase 2 study (clinical study identifier: NCT04520451) and results were presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress. In IgG4-RD patients, treatment with rilzabrutinib for 52 weeks led to reduction in disease flare, other disease markers, and glucocorticoid sparing. The safety profile of rilzabrutinib in the study was consistent with previous studies, with no new safety signals observed. In addition to IgG4-related disease, rilzabrutinib has received orphan designations for immune thrombocytopenia (ITP) in the US, the EU, and Japan; and for warm autoimmune hemolytic anemia, IgG4-RD and sickle cell disease in the US. Rilzabrutinib has also been granted fast track designation in the US in ITP and IgG4-RD. Rilzabrutinib is currently under regulatory review in the US, the EU, and China for its potential use in ITP. The target action date for the US FDA regulatory decision for ITP, which was granted fast track designation, is August 29, 2025. Rilzabrutinib is an investigational agent, and its safety and efficacy have not been evaluated by any regulatory authority. About rilzabrutinib Rilzabrutinib is a novel, advanced, oral, reversible covalent BTK inhibitor that has the potential to be an effective new medicine for several rare immune-mediated or inflammatory diseases by working to restore immune balance via multi-immune modulation. BTK, expressed in B cells, macrophages, and other innate immune cells, plays a critical role in multiple immune-mediated disease processes and inflammatory pathways. With the application of the TAILORED COVALENCY® technology, rilzabrutinib can selectively inhibit the BTK target while potentially reducing the risk of off-target side IgG4-RD IgG4-RD is a progressive, relapsing, chronic immune-mediated rare disease, which can manifest in almost every organ and can lead to organ damage and irreversible dysfunction with a sometimes-fatal outcome. People with IgG4-RD experience frequent flare-ups of the condition characterized by periods of exacerbated symptoms. It affects approximately eight out of 100,000 adult patients in the US each year. Due to its rarity and challenges with diagnosis, the global prevalence of IgG4-RD is unknown. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Li | +33 6 84 00 90 72 | Sanofi forward-looking statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press ReleaseError while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
New York Post
2 days ago
- New York Post
Texas woman claims US Marine got her pregnant, then spiked her drink with abortion pills after she refused to ‘get rid of it': lawsuit
A Texas woman claims a US Marine got her pregnant and then secretly spiked her hot chocolate with abortion pills — ending her pregnancy without her consent after she refused his repeated demands to 'get rid of it,' according to a federal lawsuit. Liana Davis filed the wrongful death suit Monday, accusing Christopher Cooprider, 34, of dissolving at least 10 misoprostol pills into a drink he gave her at her Corpus Christi home on April 5 while she was eight weeks pregnant with his child, according to the lawsuit obtained by The Post. Liana Davis accused Christopher Cooprider of dissolving at least 10 misoprostol pills into a drink he made for her at her Corpus Christi home on April 5 while she was eight weeks pregnant with his child. Getty Images Advertisement Within 30 minutes of drinking the hot chocolate, Davis began 'hemorrhaging and cramping,' while Cooprider allegedly fled the scene and stopped responding to texts, the suit — filed in the US District Court for the Southern District of Texas — claimed. 'I am gushing blood. Please hurry,' Davis texted him around 12:30 a.m. Instead, Davis's disabled mother had to take an Uber to watch her three sleeping children while a neighbor rushed the bleeding woman to the hospital. Her unborn baby, whom she had already named Joy, did not survive, documents said. Advertisement The lawsuit also alleges Cooprider ordered the abortion pills without Davis' knowledge or consent from Aid Access, an international online pill provider founded by Dutch physician Dr. Rebecca Gomperts. Both Aid Access and Gomperts were also named as defendants in the lawsuit. The alleged drink spiking followed a months-long campaign by Cooprider, a Marine pilot in training who was temporarily stationed in Corpus Christi, to pressure Davis into an abortion after she told him she might be pregnant in late January, according to the suit. 'We're not in love,' he texted her after the pregnancy was confirmed. 'It would be messed up to bring a child into the world without both parents raising them,' he said, the suit claimed. Cooprider continued to tell David to 'get rid of it' after her pregnancy test came back positive — causing her stress. Advertisement 'Every time you say 'get rid of it,' it's like an electric shock,' she wrote, according to the lawsuit. 'I literally feel like I'm going down the steepest hill on a roller coaster when I read that.' The lawsuit also alleges Cooprider ordered the abortion pills without Davis' knowledge or consent from Aid Access, an international online pill provider founded by Dutch physician Dr. Rebecca Gomperts. AP Cooprider even brought abortion pills to Davis' house several times to ask her to 'kill' her unborn baby, the suit said. He would leave the pills behind, hoping Davis would change her mind, she alleged. Despite several heated text exchanges, Cooprider failed to convince Davis to have the abortion. The Marine even threatened to testify against her in a custody battle for her three children with an ex-husband, Davis claimed. Advertisement By April, Cooprider appeared to change his tune, proposing that they have a 'trust-building' night where they'd drink warm tea and reconnect. Instead, three days later, he allegedly served her the poisoned hot cocoa. When Davis returned home from the hospital, she found the open box of abortion pills, which she handed over to Corpus Christi police. Despite the allegations, Corpus Christi police said there is no active investigation into Cooprider, NBC reported. The lawsuit seeks Cooprider, Aid Access, and Gomperts to pay undisclosed damages for the wrongful death of Davis's unborn child.
Yahoo
2 days ago
- Yahoo
Podcast: US tariff news and Q2 earnings influence pharma trends
After months of negotiations, the EU and US reached an agreement to levy a 15% tariff on EU imports, which includes including tariffs on specific sectors, like the drug imports. On this episode, the healthcare reporting team dives into the latest round of tariffs and other regulatory policies that are set to directly affect the pharma sector. GlobalData Insights Manasi Vaidya sat down to discuss the news with Robert Barrie, a reporter for Pharmaceutical Technology, who has written about several of these developments in the last few weeks. The second half of the episode also contains snippets of an interview with Dr. Mariana Socal, a health economist from the Johns Hopkins Bloomberg Public School of Health, about the short and long term consequences of these policies on the development and pricing for these drugs. Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence . "Podcast: US tariff news and Q2 earnings influence pharma trends" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
